RhumbLine Advisers
RVLP

RhumbLine Advisers’s RVL Pharmaceuticals plc Ordinary Shares RVLP Stock Holding History

RhumbLine Advisers’s Portfolio RVLP Stock Details RVLP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-16,410
Closed -$53K – 3141
2021
Q1 		$53K Buy
16,410
+875
+6% +$3.6K ﹤0.01% 2976
2020
Q4 		$64K Buy
15,535
+1,435
+10% +$8.27K ﹤0.01% 3010
2020
Q3 		$76K Sell
14,100
-2,151
-13% -$12.4K ﹤0.01% 2917
2020
Q2 		$109K Buy
16,251
+3,192
+24% +$15.6K ﹤0.01% 2949
2020
Q1 		$42K Hold
13,059
– – ﹤0.01% 2875
2019
Q4 		$91K Buy
13,059
+200
+2% +$1.07K ﹤0.01% 2880
2019
Q3 		$49K Buy
12,859
+982
+8% +$3.33K ﹤0.01% 2926
2019
Q2 		$45K Buy
+11,877
New +$39.5K ﹤0.01% 2959

Other funds holding RVLP

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
RA
Rovida Advisors Fort Lauderdale, Florida $116M AUM 12.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

RhumbLine Advisers's RVLP Position: Q2 2021 in Review

RhumbLine Advisers sold out of RVL Pharmaceuticals plc Ordinary Shares (RVLP) in Q2 2021, closing a stake of 16,410 shares — an estimated $53K sold.

RhumbLine Advisers first reported a position in RVLP in Q2 2019 and held it in 8 quarters. The position peaked at $109K in Q2 2020. 46 funds tracked by Wall St. Rank hold RVLP as of Q2 2021.

  • RhumbLine Advisers reported no remaining RVL Pharmaceuticals plc Ordinary Shares position as of Q2 2021 after selling out during the quarter.
  • RhumbLine Advisers sold 16,410 RVL Pharmaceuticals plc Ordinary Shares shares in Q2 2021, an estimated $53K.
  • RhumbLine Advisers first reported a position in RVL Pharmaceuticals plc Ordinary Shares in Q2 2019 and held it in 8 quarters.
  • RhumbLine Advisers's RVL Pharmaceuticals plc Ordinary Shares position peaked at $109K in Q2 2020.
  • 46 funds tracked by Wall St. Rank held RVL Pharmaceuticals plc Ordinary Shares as of Q2 2021.

Based on RhumbLine Advisers's 13F filing for Q2 2021, filed 5 Aug 2021.